#Seeking# #biotech# $诺华制药(NVS)$

交易对象

1 舶望制药授予诺华两款处于早研阶段分子的中国以外权益的选择权
2 BW-00112 (ANGPTL3) 产品的优先谈判权
3 另一款处于 临床前研究阶段的 siRNA 候选药物，舶望制药授予诺华独家中国地区以外许可，并包含在美国和中国分享损益 (P&L) 的互惠选择权

交易细节

舶望制药将获得 1.6 亿美元的预付款。并可能获得潜在的里程碑和期权付款以及商业销售的分级特许权使用费。

此外，诺华公司已初步意向参与舶望制药的下轮股权融资，其具体参与（包括投资金额与时间）仍需履行例行尽职调查、并由双方协商并签署正式协议来确定。

网页链接。RNAi Multi-Asset License and Option Agreements

• Agreement to explore Argo’s Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline
• License to an additional Argo siRNA candidate currently in IND-enabling studies
• Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity; Argo is also eligible to receive option payment, development, sales milestones and royalties on commercial sales